PT1429800E - Vacina e sua utilização para tratamento de esclerose lateral amiotrófica - Google Patents

Vacina e sua utilização para tratamento de esclerose lateral amiotrófica Download PDF

Info

Publication number
PT1429800E
PT1429800E PT02788511T PT02788511T PT1429800E PT 1429800 E PT1429800 E PT 1429800E PT 02788511 T PT02788511 T PT 02788511T PT 02788511 T PT02788511 T PT 02788511T PT 1429800 E PT1429800 E PT 1429800E
Authority
PT
Portugal
Prior art keywords
cop
vaccine
lateral sclerosis
amyotrophic lateral
treatment
Prior art date
Application number
PT02788511T
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of PT1429800E publication Critical patent/PT1429800E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PT02788511T 2001-12-06 2002-12-05 Vacina e sua utilização para tratamento de esclerose lateral amiotrófica PT1429800E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
PT1429800E true PT1429800E (pt) 2009-04-27

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02788511T PT1429800E (pt) 2001-12-06 2002-12-05 Vacina e sua utilização para tratamento de esclerose lateral amiotrófica

Country Status (24)

Country Link
US (1) US7351686B2 (pt)
EP (1) EP1429800B1 (pt)
JP (1) JP4542339B2 (pt)
KR (1) KR20040081431A (pt)
CN (2) CN1617736A (pt)
AT (1) ATE422362T1 (pt)
AU (1) AU2002353486B2 (pt)
CA (1) CA2469092C (pt)
CY (1) CY1109044T1 (pt)
DE (1) DE60231131D1 (pt)
DK (1) DK1429800T3 (pt)
ES (1) ES2322566T3 (pt)
HK (1) HK1067043A1 (pt)
HU (1) HU228207B1 (pt)
IL (1) IL160105A0 (pt)
IS (1) IS2670B (pt)
MX (1) MXPA04005537A (pt)
NO (1) NO336231B1 (pt)
NZ (1) NZ533356A (pt)
PL (1) PL205469B1 (pt)
PT (1) PT1429800E (pt)
RU (1) RU2303996C2 (pt)
SI (1) SI1429800T1 (pt)
WO (1) WO2003047500A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
CA2512735C (en) * 2003-01-07 2016-03-08 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
WO2005056574A2 (en) 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
EP2301569B1 (en) 2003-11-12 2018-05-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
ES2560448T3 (es) * 2004-05-07 2016-02-19 Ares Trading S.A. Procedimientos de tratamiento de enfermedades con copolímeros aleatorios
JP5241012B2 (ja) 2005-07-15 2013-07-17 ノバルティス アーゲー Ｐａｍｐｓ、病原体関連分子パターン
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
EP2195008A1 (en) 2007-09-24 2010-06-16 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2013084236A1 (en) * 2011-12-05 2013-06-13 Ben-Gurion University Of The Negev Research And Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als)
KR20140145173A (ko) * 2012-03-26 2014-12-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
WO2014037952A1 (en) 2012-09-10 2014-03-13 Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
SE505316C2 (sv) 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
US20030108528A1 (en) * 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1039929A1 (en) 1998-07-21 2000-10-04 YEDA RESEARCH AND DEVELOPMENT Co. Ltd. Activated t-cells and their uses
AU766498B2 (en) 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
ATE314860T1 (de) * 2000-06-07 2006-02-15 Yeda Res & Dev Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
IS2670B (is) 2010-09-15
AU2002353486A1 (en) 2003-06-17
JP4542339B2 (ja) 2010-09-15
ATE422362T1 (de) 2009-02-15
NZ533356A (en) 2006-10-27
CN1617736A (zh) 2005-05-18
IL160105A0 (en) 2004-06-20
DE60231131D1 (de) 2009-03-26
CN102151330B (zh) 2017-04-12
WO2003047500A3 (en) 2004-03-18
HUP0500039A3 (en) 2010-01-28
HK1067043A1 (en) 2005-04-01
WO2003047500A2 (en) 2003-06-12
DK1429800T3 (da) 2009-04-27
HU228207B1 (hu) 2013-01-28
SI1429800T1 (sl) 2009-08-31
AU2002353486B2 (en) 2009-01-15
EP1429800A4 (en) 2006-03-22
NO20042833L (no) 2004-08-12
US20050220802A1 (en) 2005-10-06
CY1109044T1 (el) 2014-07-02
KR20040081431A (ko) 2004-09-21
PL205469B1 (pl) 2010-04-30
EP1429800B1 (en) 2009-02-11
RU2303996C2 (ru) 2007-08-10
IS7296A (is) 2004-06-03
CA2469092C (en) 2013-02-19
RU2004120536A (ru) 2005-03-27
JP2005515198A (ja) 2005-05-26
US7351686B2 (en) 2008-04-01
ES2322566T3 (es) 2009-06-23
HUP0500039A2 (hu) 2005-03-29
NO336231B1 (no) 2015-06-22
EP1429800A2 (en) 2004-06-23
PL370070A1 (en) 2005-05-16
CN102151330A (zh) 2011-08-17
MXPA04005537A (es) 2004-11-01
CA2469092A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
HK1067043A1 (en) Vaccine and use thereof for treatment of amyotrophic lateral sclerosis
AU6185398A (en) Charged lipids and uses for the same
IL110045A0 (en) Pharmaceutical compositions containing oligopeptides combating aids and arc and for immune stimulation and certain such novel oligopeptides
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
ZA942035B (en) Protein formulation
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
PL399137A1 (pl) Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
MXPA04000024A (es) Metodos para inducir una respuesta inmunologica citotoxica y composiciones de adenovirus simio recombinante utiles en los mismos.
HK1049444A1 (en) Transdermal therapeutic system for parkingson's disease inducing high plasma levels of rotigotine
CA2299361A1 (en) Use of consensus interferon in combination with il-1 receptor antagonist for treatment of patients afflicted with multiple sclerosis
IL108285A0 (en) Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
NZ505538A (en) A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like